Neurocrine director granted 2,567 RSUs

POON CHRISTINE A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

POON CHRISTINE A reported acquisition or exercise transactions in this Form 4 filing.

NEUROCRINE BIOSCIENCES INC director Christine A. Poon reported an equity compensation grant of 2,567 Restricted Stock Units. Each RSU represents one share of common stock upon vesting, and the entire award is scheduled to vest in full on May 27, 2027.

Insider Trade Summary

Grant/Award: 2,567 shares

Grant/Award 1 txn

Insider POON CHRISTINE A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	2,567	$0.00	$0.00

Holdings After Transaction: Restriced Stock Unit — 2,567 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. F2. The RSUs will vest in full on May 27, 2027.

Key Figures

RSUs granted: 2,567 units RSU vesting date: May 27, 2027 Shares after transaction: 2,567 shares +1 more

4 metrics

RSUs granted 2,567 units Restricted Stock Units awarded to director Christine A. Poon

RSU vesting date May 27, 2027 RSUs vest in full on this date

Shares after transaction 2,567 shares Total underlying common shares following RSU grant

RSU grant price $0.0000 per unit Equity compensation, non-cash grant

Key Terms

Restricted Stock Unit, vest in full, common stock

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vest in full financial

"The RSUs will vest in full on May 27, 2027."

common stock financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NBIX director Christine Poon report?

Christine A. Poon reported receiving a grant of 2,567 Restricted Stock Units in Neurocrine Biosciences. This is an equity compensation award, not an open-market purchase or sale of existing shares, and is recorded as an acquisition on the Form 4 filing.

How many Neurocrine Biosciences (NBIX) RSUs were granted to the director?

The director received 2,567 Restricted Stock Units from Neurocrine Biosciences. Each RSU represents the right to receive one share of common stock upon vesting, giving the award a direct link to the company’s equity when the units fully vest.

When do Christine Poon’s NBIX Restricted Stock Units vest?

The 2,567 Restricted Stock Units granted to Christine A. Poon vest in full on May 27, 2027. On that vesting date, each RSU converts into one share of Neurocrine Biosciences common stock, assuming all standard vesting conditions are satisfied.

Are Christine Poon’s NBIX RSUs an open-market share purchase?

No, the 2,567 RSUs reported are a compensation grant, not an open-market purchase. The units were awarded at a stated price of $0.0000 per unit and will deliver Neurocrine Biosciences common shares only when they vest on May 27, 2027.

What does each Neurocrine Biosciences RSU granted to the director represent?

Each Restricted Stock Unit granted to the director represents the right to receive one share of Neurocrine Biosciences common stock. The conversion happens automatically upon vesting, aligning the director’s compensation more closely with future company share performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 06:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POON CHRISTINE A

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restriced Stock Unit(1)	$0	05/27/2026		A		2,567		(2)	(2)	Common Stock	2,567	$0	2,567	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)